Purple Biotech
NASDAQ: PPBT · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Purple Biotech (PPBT) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for PPBT.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
PPBT historical valuation range
Where current P/E sits in PPBT's own 5Y range.
PPBT intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Standard discounted cash flow models produce unreliable output for unprofitable or near-breakeven companies. Revenue-based multiples such as P/S and EV/Sales, combined with the historical valuation position above, give a more reliable read for this stock.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
PPBT valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
P/S Ratio — History
Current: 58.08x
Is PPBT overvalued in 2026?
Purple Biotech (PPBT) currently trades at $3.85 per share with a market capitalization of $2,787,500.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 26/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
PPBT currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 58.1x, the market is valuing the company primarily on its revenue rather than its earnings.
A standard DCF model does not produce reliable output for PPBT under current conditions. For unprofitable or near-breakeven companies, revenue-based multiples such as EV/Sales and historical P/S percentile are more informative than intrinsic value calculations.
Financial quality is a concern. The Piotroski F-Score of 2/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: PPBT appears richly valued on our framework, with a Smart Value Score of 26/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is PPBT overvalued?
PPBT scores 26/100 on our Smart Value Score (Grade F), a weak overall profile. A standard DCF is unreliable here given the profitability profile, so valuation leans on revenue-based measures like EV/Sales and the P/S percentile below.
What is PPBT's fair value?
A standard DCF is unreliable for PPBT given its current profitability profile. Revenue-based approaches like EV/Sales or the historical P/S percentile are more informative for this stock.
What P/E ratio does PPBT trade at?
PPBT does not have a meaningful P/E right now, usually a sign of unprofitability or an earnings transition. For unprofitable growth names, price-to-sales is the more useful gauge.
Is PPBT a buy based on valuation?
Our Smart Value rating for PPBT is Strong Sell, from a Smart Value Score of 26/100 that blends growth, quality, and valuation. The profile skews cautious, and a better price or clearer operating improvement would strengthen the case. This is research to inform your decision, not personalized financial advice.
How does PPBT's valuation compare to its history?
There is not enough historical valuation data yet for a confident percentile read on PPBT.
What is PPBT's Smart Value Score?
PPBT's Smart Value Score is 26/100. It is a proprietary WallStSmart metric blending growth quality, financial health, and valuation into a single 0-100 read, and scores above 75 are rare, signaling strong multi-factor alignment.